Lynch & Associates IN Has $6.01 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Lynch & Associates IN grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.9% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,721 shares of the company’s stock after buying an additional 143 shares during the period. Eli Lilly and Company makes up 1.4% of Lynch & Associates IN’s investment portfolio, making the stock its 24th largest holding. Lynch & Associates IN’s holdings in Eli Lilly and Company were worth $6,007,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Versant Capital Management Inc raised its holdings in Eli Lilly and Company by 1.8% in the 1st quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock worth $573,000 after purchasing an additional 13 shares during the period. Moseley Investment Management Inc. raised its holdings in shares of Eli Lilly and Company by 0.4% during the 1st quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock worth $3,027,000 after acquiring an additional 14 shares during the period. Buckhead Capital Management LLC boosted its position in shares of Eli Lilly and Company by 0.7% during the 4th quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock valued at $1,226,000 after acquiring an additional 15 shares during the last quarter. Levin Capital Strategies L.P. grew its holdings in shares of Eli Lilly and Company by 3.8% in the fourth quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock valued at $242,000 after purchasing an additional 15 shares during the period. Finally, Clearwater Capital Advisors LLC increased its position in Eli Lilly and Company by 1.3% during the fourth quarter. Clearwater Capital Advisors LLC now owns 1,202 shares of the company’s stock worth $701,000 after purchasing an additional 15 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock opened at $886.33 on Friday. The firm has a 50 day moving average of $795.93 and a 200-day moving average of $725.85. Eli Lilly and Company has a 12-month low of $434.34 and a 12-month high of $905.45. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The company has a market cap of $842.38 billion, a price-to-earnings ratio of 130.53, a PEG ratio of 1.94 and a beta of 0.36.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same period last year, the company posted $1.62 EPS. The company’s revenue was up 26.0% on a year-over-year basis. As a group, equities analysts expect that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were paid a dividend of $1.30 per share. The ex-dividend date was Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.59%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Analyst Ratings Changes

Several brokerages have recently commented on LLY. Truist Financial upped their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Bank of America upped their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Jefferies Financial Group upped their price target on Eli Lilly and Company from $925.00 to $957.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, BMO Capital Markets upped their price target on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $803.50.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 194,978 shares of the business’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $885.91, for a total value of $172,732,959.98. Following the transaction, the insider now owns 97,583,810 shares in the company, valued at approximately $86,450,473,117.10. The disclosure for this sale can be found here. Insiders sold a total of 762,804 shares of company stock valued at $648,109,138 in the last ninety days. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.